コンテンツへスキップ
Merck

Trimethoprim-sulfamethoxazole for bacterial meningitis.

Annals of internal medicine (1984-06-01)
R E Levitz, R Quintiliani
要旨

Trimethoprim-sulfamethoxazole has excellent microbiologic activity against most pathogens that produce meningitis; both components of this drug have high penetration into tissues, including the cerebrospinal fluid. Clinical experience shows that trimethoprim-sulfamethoxazole may be beneficial in the treatment of gram-negative bacillary meningitis caused by organisms only moderately susceptible to third-generation cephalosporins (Enterobacter cloacae, Serratia marcescens) or resistant to these antibiotic agents (Pseudomonas cepacia, Acinetobacter). The success of trimethoprim-sulfamethoxazole in the treatment of four patients with Staphylococcus aureus and two patients with Listeria monocytogenes meningitis shows that this drug may also be useful in treating infrequent types of gram-positive meningitis.

材料
製品番号
ブランド
製品内容

Supelco
スルファメトキサゾール
Supelco
スルファメトキサゾール, Pharmaceutical Secondary Standard; Certified Reference Material
USP
スルファメトキサゾール, United States Pharmacopeia (USP) Reference Standard
Supelco
スルファメトキサゾール, VETRANAL®, analytical standard
スルファメトキサゾール, European Pharmacopoeia (EP) Reference Standard
Supelco
スルファメトキサゾール, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland